Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 17, Issue 11, Pages 4549-4552Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2021.1947762
Keywords
Plasmodium falciparum; malaria vaccine; malaria elimination
Categories
Ask authors/readers for more resources
Malaria vaccines, including the RTS,S/AS01 vaccine, are showing moderate efficacy and new approaches are being developed for next-generation vaccines. Techniques such as RNA vaccine delivery and whole organism vaccination are being explored, with the goal of creating highly effective malaria vaccines that provide sustained protection.
Malaria vaccines hold significant promise for life-saving benefit, especially to children who bear the major burden of malaria mortality. The RTS,S/AS01 malaria vaccine provides moderate efficacy and is being tested in implementation studies. In parallel, multiple strategies are being advanced to test next-generation malaria vaccines, including novel approaches that build on principles learned from RTS,S development, vaccination with radiation-attenuated sporozoites, and development of monoclonal antibodies targeting immunogenic peptides. Novel vaccine delivery approaches are also being advanced, including self-amplifying RNA vaccine delivery, self-assembling protein nanoparticle methods, circumsporozoite protein-based approaches, and whole organism vaccination. Techniques employed for COVID-19 vaccine development should also be considered for malaria vaccination, including sustained release polymer nanoparticle hydrogel vaccination and charge-altering releasable transporters. As vaccine science advances and new approaches optimize knowledge gained, highly effective malaria vaccines that provide sustained protection are within reach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available